Publication | Closed Access

Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

Hematological MalignancyResidual DiseaseMolecular MonitoringOncologyMedicineHematologyImmunologyPathologyImmunologic DiseaseInterferon AlphaMolecular DiagnosticsMolecular MedicineMyeloid Neoplasia